FI66595C - Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-minocyklopent-1-en-1-tiokarbonyldisulfider - Google Patents
Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-minocyklopent-1-en-1-tiokarbonyldisulfider Download PDFInfo
- Publication number
- FI66595C FI66595C FI773967A FI773967A FI66595C FI 66595 C FI66595 C FI 66595C FI 773967 A FI773967 A FI 773967A FI 773967 A FI773967 A FI 773967A FI 66595 C FI66595 C FI 66595C
- Authority
- FI
- Finland
- Prior art keywords
- dopamine
- acid
- ene
- noradrenaline
- hydroxylase
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 6
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 38
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 24
- 229960002748 norepinephrine Drugs 0.000 description 24
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 24
- 229960003638 dopamine Drugs 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 11
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 description 11
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 229940076279 serotonin Drugs 0.000 description 7
- -1 2-aminocyclopent-1-en-1-thiocarbonyl Chemical group 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- DGMPVYSXXIOGJY-UHFFFAOYSA-N Fusaric acid Chemical compound CCCCC1=CC=C(C(O)=O)N=C1 DGMPVYSXXIOGJY-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000004100 adrenal gland Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 150000003943 catecholamines Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- SPZDBFZHUCNYLS-UHFFFAOYSA-N (2-aminocyclopentene-1-carbothioyl)sulfanyl 2-aminocyclopentene-1-carbodithioate Chemical class C1CCC(N)=C1C(=S)SSC(=S)C1=C(N)CCC1 SPZDBFZHUCNYLS-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- KSRBLMBTFSXSBM-UHFFFAOYSA-N [2-(ethylamino)cyclopentene-1-carbothioyl]sulfanyl 2-(ethylamino)cyclopentene-1-carbodithioate Chemical compound C1CCC(NCC)=C1C(=S)SSC(=S)C1=C(NCC)CCC1 KSRBLMBTFSXSBM-UHFFFAOYSA-N 0.000 description 3
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 3
- 229960002563 disulfiram Drugs 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- NXJOFTRBTBDSHB-UHFFFAOYSA-N (4-methyl-1,4-diazepane-1-carbothioyl)sulfanyl 4-methyl-1,4-diazepane-1-carbodithioate Chemical compound C1CN(C)CCCN1C(=S)SSC(=S)N1CCN(C)CCC1 NXJOFTRBTBDSHB-UHFFFAOYSA-N 0.000 description 2
- GCZZOZBWAZHCAN-UHFFFAOYSA-N 1-phenyl-3-(1,3-thiazol-2-yl)thiourea Chemical compound C=1C=CC=CC=1NC(=S)NC1=NC=CS1 GCZZOZBWAZHCAN-UHFFFAOYSA-N 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 241000906446 Theraps Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- OEWKQEHUGWGZKS-UHFFFAOYSA-N [2-(cyclohexylamino)cyclopentene-1-carbothioyl]sulfanyl 2-(cyclohexylamino)cyclopentene-1-carbodithioate Chemical compound C1(CCCCC1)NC1=C(CCC1)C(=S)SSC(=S)C1=C(CCC1)NC1CCCCC1 OEWKQEHUGWGZKS-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 229950004394 ditiocarb Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002474 noradrenergic effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- SPFUGDSFNDDSBJ-UHFFFAOYSA-N (2-aminocyclopenten-1-yl)-[bis(sulfanylidene)-$l^{6}-sulfanylidene]methanol Chemical class NC1=C(C(O)=S(=S)=S)CCC1 SPFUGDSFNDDSBJ-UHFFFAOYSA-N 0.000 description 1
- XMPRFBUTGLVJQS-HTQCVBHVSA-N (E)-[(2S)-1-[[(E)-but-2-enoyl]amino]-3-methylbutan-2-yl]-hydroxyimino-oxidoazanium Chemical compound C\C=C\C(=O)NC[C@H](C(C)C)[N+](\[O-])=N/O XMPRFBUTGLVJQS-HTQCVBHVSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QYPKEVDTCBHOMB-UHFFFAOYSA-N ClC=1N=C(C(=O)O)C=CC1CCC Chemical compound ClC=1N=C(C(=O)O)C=CC1CCC QYPKEVDTCBHOMB-UHFFFAOYSA-N 0.000 description 1
- FJUBKTNNXRFHFD-WTSVBCDHSA-N Dopastin Natural products C\C=C\C(=O)NC[C@H](C(C)C)N(O)N=O FJUBKTNNXRFHFD-WTSVBCDHSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- OFELWPIUPPMBTA-UHFFFAOYSA-N Oosponol Natural products OCC(=O)C1=Cc2cccc(O)c2C(=O)O1 OFELWPIUPPMBTA-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- RUZDWVDIAHNLGQ-UHFFFAOYSA-N [2-(butylamino)cyclopentene-1-carbothioyl]sulfanyl 2-(butylamino)cyclopentene-1-carbodithioate Chemical compound C(CCC)NC1=C(CCC1)C(=S)SSC(=S)C1=C(CCC1)NCCCC RUZDWVDIAHNLGQ-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- NHOWLEZFTHYCTP-UHFFFAOYSA-N benzylhydrazine Chemical compound NNCC1=CC=CC=C1 NHOWLEZFTHYCTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 229940116901 diethyldithiocarbamate Drugs 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 150000004659 dithiocarbamates Chemical class 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- WRIZJEREXIDJCC-UHFFFAOYSA-N oosponol Chemical compound C1=CC=C2C(C(=O)CO)=COC(=O)C2=C1O WRIZJEREXIDJCC-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU76RI610A HU175526B (hu) | 1976-12-30 | 1976-12-30 | Sposob poluchenija 2-amino-ciklopent-1-en-1-ditiokarbonovykh-disul'fidov |
| HURI000610 | 1976-12-30 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI773967A7 FI773967A7 (fi) | 1978-07-01 |
| FI66595B FI66595B (fi) | 1984-07-31 |
| FI66595C true FI66595C (fi) | 1984-11-12 |
Family
ID=11001014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI773967A FI66595C (fi) | 1976-12-30 | 1977-12-29 | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-minocyklopent-1-en-1-tiokarbonyldisulfider |
Country Status (21)
| Country | Link |
|---|---|
| JP (1) | JPS5384949A (OSRAM) |
| AR (1) | AR216308A1 (OSRAM) |
| AT (1) | AT351501B (OSRAM) |
| AU (1) | AU516353B2 (OSRAM) |
| BE (1) | BE862408A (OSRAM) |
| CH (1) | CH631701A5 (OSRAM) |
| DE (1) | DE2758809A1 (OSRAM) |
| ES (1) | ES465567A1 (OSRAM) |
| FI (1) | FI66595C (OSRAM) |
| FR (1) | FR2376132A1 (OSRAM) |
| GB (1) | GB1582716A (OSRAM) |
| HU (1) | HU175526B (OSRAM) |
| IL (1) | IL53646A (OSRAM) |
| IN (1) | IN146470B (OSRAM) |
| NL (1) | NL7714514A (OSRAM) |
| NO (1) | NO145237C (OSRAM) |
| PT (1) | PT67482B (OSRAM) |
| SE (1) | SE7714526L (OSRAM) |
| SU (1) | SU743580A3 (OSRAM) |
| YU (1) | YU309677A (OSRAM) |
| ZA (1) | ZA777573B (OSRAM) |
-
1976
- 1976-12-30 HU HU76RI610A patent/HU175526B/hu unknown
-
1977
- 1977-12-19 IL IL53646A patent/IL53646A/xx unknown
- 1977-12-20 ZA ZA00777573A patent/ZA777573B/xx unknown
- 1977-12-20 AT AT912077A patent/AT351501B/de not_active IP Right Cessation
- 1977-12-20 SE SE7714526A patent/SE7714526L/ not_active Application Discontinuation
- 1977-12-21 CH CH1582477A patent/CH631701A5/de not_active IP Right Cessation
- 1977-12-23 AU AU31979/77A patent/AU516353B2/en not_active Expired
- 1977-12-26 FR FR7739183A patent/FR2376132A1/fr active Granted
- 1977-12-27 IN IN1772/CAL/77A patent/IN146470B/en unknown
- 1977-12-27 YU YU03096/77A patent/YU309677A/xx unknown
- 1977-12-28 SU SU772559902A patent/SU743580A3/ru active
- 1977-12-28 BE BE183912A patent/BE862408A/xx not_active IP Right Cessation
- 1977-12-29 AR AR270573A patent/AR216308A1/es active
- 1977-12-29 FI FI773967A patent/FI66595C/fi not_active IP Right Cessation
- 1977-12-29 NL NL7714514A patent/NL7714514A/xx not_active Application Discontinuation
- 1977-12-29 NO NO774502A patent/NO145237C/no unknown
- 1977-12-29 JP JP15853077A patent/JPS5384949A/ja active Pending
- 1977-12-29 GB GB54173/77A patent/GB1582716A/en not_active Expired
- 1977-12-29 ES ES465567A patent/ES465567A1/es not_active Expired
- 1977-12-29 PT PT67482A patent/PT67482B/pt unknown
- 1977-12-30 DE DE19772758809 patent/DE2758809A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AT351501B (de) | 1979-07-25 |
| CH631701A5 (en) | 1982-08-31 |
| BE862408A (fr) | 1978-04-14 |
| FI66595B (fi) | 1984-07-31 |
| JPS5384949A (en) | 1978-07-26 |
| FI773967A7 (fi) | 1978-07-01 |
| IN146470B (OSRAM) | 1979-06-09 |
| SU743580A3 (ru) | 1980-06-25 |
| PT67482B (en) | 1979-05-30 |
| AU516353B2 (en) | 1981-05-28 |
| NO774502L (no) | 1978-07-03 |
| SE7714526L (sv) | 1978-07-01 |
| DE2758809A1 (de) | 1978-07-06 |
| NL7714514A (nl) | 1978-07-04 |
| ATA912077A (de) | 1979-01-15 |
| YU309677A (en) | 1983-01-21 |
| GB1582716A (en) | 1981-01-14 |
| ZA777573B (en) | 1978-10-25 |
| AR216308A1 (es) | 1979-12-14 |
| ES465567A1 (es) | 1979-01-01 |
| NO145237C (no) | 1982-02-10 |
| IL53646A (en) | 1982-03-31 |
| HU175526B (hu) | 1980-08-28 |
| FR2376132B1 (OSRAM) | 1979-10-19 |
| PT67482A (en) | 1978-01-01 |
| IL53646A0 (en) | 1978-03-10 |
| FR2376132A1 (fr) | 1978-07-28 |
| NO145237B (no) | 1981-11-02 |
| AU3197977A (en) | 1979-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2871920C (en) | Permeable glycosidase inhibitors and uses thereof | |
| EP1163029B1 (en) | Nitrate esters and their use for inducing neuroprotection and cognition enhancement | |
| JP5976322B2 (ja) | テトラヒドロ−イミダゾ［１，５−ａ］ピラジン誘導体塩、その製造方法及び医薬用途 | |
| Angeli et al. | Design, synthesis and X-ray crystallography of selenides bearing benzenesulfonamide moiety with neuropathic pain modulating effects | |
| US4761404A (en) | Phospholipid analogs useful as PAF synthesis inhibitors | |
| JP2012519193A5 (OSRAM) | ||
| US20140045809A1 (en) | Corroles for neuroprotection and neurorescue | |
| FI66595B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-minocyklopent-1-en-1-tiokarbonyldisulfider | |
| US5244917A (en) | Substituted naphthofurans as anti-inflammatory agents | |
| CH638221A5 (fr) | Oximes derivees de l'acide 3-substitue 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et les compositions pharmaceutiques les renfermant. | |
| CN119504753A (zh) | 一种芳香稠环亚胺类化合物及其制备方法和应用 | |
| CN112118837B (zh) | 抗菌剂：o-烷基氘化派洛宁 | |
| Yevich et al. | Antiallergics: 3-(1H-tetrazol-5-yl)-4H-pyrimido [2, 1-b] benzothiazol-4-ones | |
| FI66845C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara n-ubstituerade 2-aminocyklopent-1-en-1-ditiokarboxylsyror | |
| Hassan | Synthesis, characterization, anti-inflammatory, and antioxidant activities of some new thiazole derivatives | |
| JP2019518029A (ja) | グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法 | |
| Hedvati et al. | Cinnamic acid derived oxazolinium ions as novel cytotoxic agents | |
| JP2010526046A (ja) | 置換ホスホネートおよびアミロイド凝集体の減少におけるその使用 | |
| FR2572401A1 (fr) | Nouveaux derives du cyano-2 benzimidazole, leur preparation et leur utilisation comme fongicides et acaricides | |
| EP0847999A1 (fr) | Dérivés de N-benzylpipérazine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| JP5497064B2 (ja) | グルコキナーゼ活性化因子として有用なアリールシクロプロピルアセトアミド誘導体 | |
| WO2013166654A1 (en) | Permeable glycosidase inhibitors and uses thereof | |
| CN118239906A (zh) | 一类可由活性氧激活的器官靶向型重金属铜清除前药及其制备方法和应用 | |
| AU783713B2 (en) | Anti-ischemic compounds | |
| EP2424515B1 (de) | Derivate von n omega-hydroxy-l-arginin zur behandlung von krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: RICHTER GEDEON VEGYESZETI GYAR R. T. |